Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model

Critical Care Medicine

Volumn 30, Issue 12, 2002, Pages 2689-2699

  Schiffer, Eduardo R C ^a   Reber, Guido ^a   De Moerloose, Philippe ^a   Morel, Denis R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Disseminated intravascular coagulation; Endotoxemia; Heparin; Hirudin; Sheep

Indexed keywords

ESCHERICHIA COLI ENDOTOXIN; HEPARIN; LIQUEMINE; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR; ANTICOAGULANT AGENT; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFICACY; ENDOTOXEMIA; FEMALE; HEART RIGHT VENTRICLE FAILURE; HYPOTENSION; LUNG EDEMA; LUNG HEMORRHAGE; LUNG INSUFFICIENCY; MALE; METABOLIC ACIDOSIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; SEPTIC SHOCK; SHEEP; SURVIVAL RATE; ANALYSIS OF VARIANCE; ANIMAL; ANTICOAGULANT THERAPY; COMPARATIVE STUDY; EVALUATION; HEMODYNAMICS; MICROPHOTOGRAPHY; PATHOLOGY; SURVIVAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMODYNAMIC PROCESSES; HEPARIN; HIRUDIN THERAPY; MALE; PHOTOMICROGRAPHY; RANDOM ALLOCATION; RECOMBINANT PROTEINS; SHEEP; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 0036884205     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200212000-00013     Document Type: Article

References (48)

1. Corrigan J Jr, Jordan CM: Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med 1970; 283:778-782
2. Bone RC: Modulators of coagulation. A critical appraisal of their role in sepsis. Arch Intern Med 1992; 152:1381-1389
3. Fourrier F, Jourdain M, Tournoys A, et al: Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock. Shock 1998; 10:364-370
4. Minnema MC, Chang AC, Jansen PM, et al: Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95:1117-1123
5. Eisele B, Lamy M, Thijs LG, et al: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, doubleblind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24:663-672
6. Baudo F, Caimi TM, de Cataldo F, et al: Antithrombin III (AT III) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double blind, randomized, multicenter study. Intensive Care Med 1998; 24:336-342
7. Markwardt F: Untersuchungen über Hirudin. Naturwissenschaften 1955; 42:537-538
8. Markwardt F: Hirudin as an inhibitor of thrombin. Methods Enzymol 1970; 19:924-932
9. Agnelli G, Pascucci C, Cosmi B, et al: The comparative effect of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990; 63:204-207
10. Dodt J, Machleidt W, Seemüller U, et al: Isolation and characterization of hirudin isoinhibitors and sequence analysis of hirudin. Biol Chem Hoppe Seyler 1986; 367:803-811
11. Hoffmann H, Siebeck M, Spannagl M, et al: Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs. Am Rev Respir Dis 1990; 142:782-788
12. Pittet JF, Morel DR, Steinig D, et al: Beneficial effect of heparin on a lethal constant rate infusion of Escherichia coli endotoxin in sheep. Abstr. Am Rev Respir Dis 1989; 139:A271
13. Schulz DR, Becker EL: The alteration of endotoxin by post-heparin plasma and its purified fractions. J Immunol 1967; 98:482-489
14. Gans H: Mechanism of heparin protection in endotoxin shock. Surgery 1975; 77:602-606
15. 1. Thromb Res 1979; 16:507-516
16. Meri S, Pangburn MK: Discrimination between activators and non-activators of the alternative pathway of complement: Regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A 1990; 87:3982-3986
17. Lantz M, Thysell H, Nilsson E, et al: On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991; 88:2026-2031
18. Hocking D, Ferro TJ, Johnson A: Dextran sulfate and heparin inhibit platelet-activating factor-induced pulmonary edema. J Appl Physiol 1992; 72:179-185
19. Yokokawa K, Tahara H, Kohno M, et al: Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest 1993; 92:2080-2085
20. Piatti PM, Monti LD, Valsecchi G, et al: Effects of low-dose heparin infusion on arterial endothelin-1 release in humans. Circulation 1996; 94:2703-2707
21. 2+ channel antagonism. Eur J Pharmacol 1999; 370:57-61
22. Lever R, Hoult JR, Page CP: The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000; 129:533-540
23. Sakurai H, Johnigan R, Kikuchi Y: Effect of reduced bronchial circulation on lung fluid flux after smoke inhalation in sheep. J Appl Physiol 1998; 84:980-986
24. Levy M, Ten Cate H, Van Der Poll T, et al: Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270:975-979
25. Klement P, Hirsch J, Johnston M, et al: Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. J Lab Clin Med 1998; 132:181-185
26. Ofosu FA: Modulation of the enzymatic activity of α-thrombin by polyanions: Consequences of intrinsic activation of factor V and factor VIII. Haemostasis 1991; 21:240-247
27. Lindhout T, Blezer R, Hemker HC: The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64:464-568
28. Moore KL, Andreoli SP, Esmon NL, et al: Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79:124-130
29. Ito T, Asai F, Oshima T, et al: Role of activated platelets in endotoxin-induced DIC in rats. Thromb Res 1990; 59:735-747
30. Gomez C, Paramo JA, Colucci M, et al: Effect of heparin and/or antithrombin III on the generation of endotoxin-induced plasminogen activator inhibitor. Thromb Haemost 1989; 62:694-698
31. Orbe J, Montes R, Zabalegui N, et al: Evidence that heparin but not hirudin reduces PAI-1 expression in cultured human endothelial cells. Thromb Res 1999; 94:137-145
32. Almeda S, Rosenberg RD, Bing DH: The binding properties of human complement component C1q. J Biol Chem 1983; 258:785-791
33. 1α during subacute endotoxin-induced hyperdynamic sepsis or multiple organ failure syndrome in sheep. Circ Shock 1991; 35:65-77
34. Morel DR, Lacroix JS, Hemsen A, et al: Increased plasma and pulmonary lymph levels of endothelin during endotoxin shock. Eur J Pharmacol 1989; 167:427-428
35. Boulanger CM, Luscher TF: Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta. Circ Res 1991; 68:1768-1772
36. Chang SW, Feddersen CO, Henson PM, et al: Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987; 79:1498-1509
37. Flick MR, Hoeffel JM, Staub NC: Superoxide dismutase with heparin prevents increased lung vascular permeability during air emboli in sheep. J Appl Physiol 1983; 55:1284-1291
38. Cox CS Jr, Zwischenberger JB, Traber DL, et al: Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet 1993; 176:339-349
39. Spannagl M, Hoffmann H, Siebeck M, et al: A purified antithrombin III-heparin complex as a potent inhibitor of thrombin in porcine endotoxin shock. Thrornb Res 1991; 61:1-10
40. Griffin MP, Gore DC, Zwischenberger JB, et al: Does heparin improve survival in experimental porcine Gram-negative septic shock? Circ Shock 1990; 31:343-349
41. Du Toit HJ, Coetzee AR, Chalton DO: Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon. Crit Care Med 1991; 19:1195-1200
42. Wang P, Ba ZF, Reich SS, et al: Effects of nonanticoagulant heparin on cardiovascular and hepatocellular function after hemorrhagic shock. Am J Physiol 1996; 270:H1294-1302
43. Zawilska K, Zozulinska M, Turowiecka Z, et al: The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits. Thromb Res 1993; 69:315-320
44. Cicala C, Bucci MR, Maraganore JM, et al: Hirulog effect in rat endotoxin shock. Life Science 1995; 57:307-313
45. Siebeck M, Spannagl M, Bichler J: Delayed treatment with desulfato-hirudin prevents fibrin formation in lipopolysaccharide-induced shock. Thromb Res 1997; 88:473-480
46. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86:51-56
47. Pernerstorfer T, Hollenstein U, Hansen JB, et al: Lepirudin blunts endotoxin-induced coagulation activation. Blood 2000; 95:1729-1734
48. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:759-762